Basilea Pharmaceutica is a revenue-generating biotech company that is on the cusp of breaking even (2021e) and sustainable profitability thereafter. It has successfully brought two anti-infective drugs to the market: Cresemba (severe mould infections) and Zevtera (bacterial infections). Combined revenue contributions (as reported by Basilea, both assets are commercialised through partners) are expected to exceed CHF105m in FY19. Longer-term value creation is also dependent on crystallising th
07 Jan 2020
Basilea Pharmaceutica - 2020 vision on derazantinib in iCCA
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Basilea Pharmaceutica - 2020 vision on derazantinib in iCCA
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
07 Jan 2020 -
Author:
Dr Susie Jana -
Pages:
16
Basilea Pharmaceutica is a revenue-generating biotech company that is on the cusp of breaking even (2021e) and sustainable profitability thereafter. It has successfully brought two anti-infective drugs to the market: Cresemba (severe mould infections) and Zevtera (bacterial infections). Combined revenue contributions (as reported by Basilea, both assets are commercialised through partners) are expected to exceed CHF105m in FY19. Longer-term value creation is also dependent on crystallising th